Cover Image
市場調查報告書

血友病的全球市場分析:各類型 (A型血友病,B型血友病,C型血友病),不同治療 (個人需求,預防),各療法 (替代療法,免疫耐受性誘導療法,基因治療),市場區隔預測

Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024

出版商 Grand View Research, Inc. 商品編碼 368045
出版日期 內容資訊 英文 84 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血友病的全球市場分析:各類型 (A型血友病,B型血友病,C型血友病),不同治療 (個人需求,預防),各療法 (替代療法,免疫耐受性誘導療法,基因治療),市場區隔預測 Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024
出版日期: 2016年08月07日 內容資訊: 英文 84 Pages
簡介

本報告提供全球血友病市場相關調查,彙整產業預測,以及各類型,不同治療,療法,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 血友病產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場趨勢
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 優先的主要機會
  • 波特產業分析
  • PESTEL分析

第4章 各類型預測

  • 各類型市場佔有率
  • A型血友病
  • B型血友病
  • C型血友病
  • 其他

第5章 血友病治療預測

  • 不同治療市場佔有率
  • 個人需求
  • 預防

第6章 各療法預測

  • 各療法市場佔有率
  • 重組的療法
  • 免疫耐受性誘導療法
  • 基因治療

第7章 各地區預測

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • Novo Nordisk
  • Biogen
  • 中外製藥株式會社
  • Bayer Healthcare
  • Pfizer, Inc.
  • Shire Plc.
  • Baxalta
  • CSL Behring
  • Octopharma

圖表

目錄

Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Further Key Findings From the Study Suggest:

Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.

For instance, Grifols has launched the "AlphaNine SD Copay Card" and "ALPHANATE Copay Program" for immediate enrollment in prophylaxis treatment by patients.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.

Table of Content

Chapter 1. Methodology And Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Hemophilia: Industry Snapshot and Key Buying Criteria, 2015 - 2024

Chapter 3. Hemophilia Industry Outlook

  • 3.1. Market Segmentation
  • 3.2. Market Size and Growth Prospects
  • 3.3. Hemophilia: Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Key Opportunities Prioritized
  • 3.5. Industry Analysis: Porter's
  • 3.6. Hemophilia Market PESTEL Analysis, 2015

Chapter 4. Hemophilia Type Outlook

  • 4.1. Hemophilia Market Share by Type, 2015 & 2024
  • 4.2. Hemophilia A
    • 4.2.1. Hemophilia A market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.3. Hemophilia B
    • 4.3.1. Hemophilia B market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.4. Hemophilia C
    • 4.4.1. Hemophilia C market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)

Chapter 5. Hemophilia Treatment Outlook

  • 5.1. Hemophilia Market Share by Treatment, 2015 & 2024
  • 5.2. On-demand
    • 5.2.1. On-demand based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
  • 5.3. Prophylaxis
    • 5.3.1. Prophylaxis-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

Chapter 6. Hemophilia Therapy Outlook

  • 6.1. Hemophilia Market Share by Therapy, 2015 & 2024
  • 6.2. Recombinant Therapy
    • 6.2.1. Recombinant therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
  • 6.3. Immune Tolerance Induction (ITI) Therapy
    • 6.3.1. ITI therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
  • 6.4. Gene Therapy
    • 6.4.1. Gene therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

Chapter 7. Hemophilia Regional Outlook

  • 7.1. Hemophilia Market Share by Region, 2015 & 2024
  • 7.2. North America
    • 7.2.1. North America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
    • 7.2.2. North America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
      • 7.2.2.1. U.S. market estimates and forecasts
      • 7.2.2.2. Canada market estimates and forecasts
  • 7.3. Europe
    • 7.3.1. Europe market estimates and forecasts, by type, 2013 - 2024 (USD Million)
    • 7.3.2. Europe market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
      • 7.3.2.1. UK market estimates and forecasts
      • 7.3.2.2. Germany market estimates and forecasts
  • 7.4. Asia-Pacific
    • 7.4.1. Asia-Pacific market estimates and forecasts, by type, 2013 - 2024 (USD Million)
    • 7.4.2. Asia-Pacific market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
      • 7.4.2.1. Japan market estimates and forecasts
      • 7.4.2.2. China market estimates and forecasts
  • 7.5. Latin America
    • 7.5.1. Latin America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
    • 7.5.2. Latin America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
      • 7.5.2.1. Brazil market estimates and forecasts
      • 7.5.2.2. Mexico market estimates and forecasts
  • 7.6. Middle East and Africa (MEA)
    • 7.6.1. MEA market estimates and forecasts, by type, 2013 - 2024 (USD Million)
    • 7.6.2. MEA market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
      • 7.6.2.1. South Africa market estimates and forecasts
      • 7.6.2.2. Saudi Arabia market estimates and forecasts

Chapter 8. Competitive Landscape

  • 8.1. Novo Nordisk
    • 8.1.1. Company profile
    • 8.1.2. Financial performance
    • 8.1.3. Product portfolio
    • 8.1.4. Strategic initiatives
  • 8.2. Biogen
    • 8.2.1. Company profile
    • 8.2.2. Financial performance
    • 8.2.3. Product portfolio
    • 8.2.4. Strategic initiatives
  • 8.3. Chugai Pharmaceutical Co.
    • 8.3.1. Company profile
    • 8.3.2. Financial performance
    • 8.3.3. Product portfolio
    • 8.3.4. Strategic initiatives
  • 8.4. Bayer Healthcare
    • 8.4.1. Company profile
    • 8.4.2. Financial performance
    • 8.4.3. Product portfolio
    • 8.4.4. Strategic initiatives
  • 8.5. Pfizer, Inc.
    • 8.5.1. Company profile
    • 8.5.2. Financial performance
    • 8.5.3. Product portfolio
    • 8.5.4. Strategic initiatives
  • 8.6. Shire Plc.
    • 8.6.1. Company profile
    • 8.6.2. Financial performance
    • 8.6.3. Product portfolio
    • 8.6.4. Strategic initiatives
  • 8.7. Baxalta
    • 8.7.1. Company profile
    • 8.7.2. Financial performance
    • 8.7.3. Product portfolio
    • 8.7.4. Strategic initiatives
  • 8.8. CSL Behring
    • 8.8.1. Company profile
    • 8.8.2. Financial performance
    • 8.8.3. Product portfolio
    • 8.8.4. Strategic initiatives
  • 8.9. Octopharma
    • 8.9.1. Company profile
    • 8.9.2. Financial performance
    • 8.9.3. Product portfolio
    • 8.9.4. Strategic initiatives

List of Tables

  • TABLE 1: Hemophilia market - Industry summary & key buying criteria
  • TABLE 2: Hemophilia market, by type, 2013 - 2024 (USD Million)
  • TABLE 3: Hemophilia market, by treatment, 2013 - 2024 (USD Million)
  • TABLE 4: Hemophilia market, by therapy, 2013 - 2024 (USD Million)
  • TABLE 5: Hemophilia market, by region, 2013 - 2024 (USD Million)
  • TABLE 6: Hemophilia market- Key market driver analysis
  • TABLE 7: Hemophilia market- Key market restraint analysis
  • TABLE 8: North America hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 9: North America hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 10: North America hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 11: U.S. hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 12: U.S. hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 13: U.S. hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 14: Canada hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 15: Canada hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 16: Canada hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 17: Europe hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 18: Europe hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 19: Europe hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 20: UK hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 21: UK hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 22: UK hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 23: Germany hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 24: Germany hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 25: Germany hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 26: Asia-Pacific hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 27: Asia-Pacific hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 28: Asia-Pacific hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 29: Japan hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 30: Japan hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 31: Japan hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 32: China hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 33: China hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 34: China hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 35: Latin America hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 36: Latin America hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 37: Latin America hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 38: Brazil hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 39: Brazil hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 40: Brazil hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 41: Mexico hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 42: Mexico hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 43: Mexico hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 44: MEA hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 45: MEA hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 46: MEA hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 50: South Africa hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 47: South Africa hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 48: South Africa hemophilia market, by therapy 2013 - 2024 (USD Million)
  • TABLE 49: Saudi Arabia hemophilia market, by type 2013 - 2024 (USD Million)
  • TABLE 50: Saudi Arabia hemophilia market, by treatment 2013 - 2024 (USD Million)
  • TABLE 51: Saudi Arabia hemophilia market, by therapy 2013 - 2024 (USD Million)
Back to Top